Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
October 26, 2018
Neuralstem (CUR) $2.1 M is executing a $2.1 M or 3 M share RDO priced at $0.70
October 14, 2018
How an Alzheimer's Success Highlights the Failures in Alzheimer's Drug Research
October 10, 2018
Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00
September 21, 2018
Fate Therapeutics (FATE) priced their 9,250,260 share offering at $13.50 for an aggregate of approximately $125 million
September 20, 2018
CRISPR Therapeutics (CRSP) prices 4.210526 M shares at $47.50, a $200 M offering with a $30 M underwriting option
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
September 5, 2018
Vericel (VCEL) gains as former competitor Histogenicss (HSGX) fails to meet endpoints
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 16, 2018
RegMed Investors’ (RMi): call me crazy if I had all the answers but, I have more than most …
July 6, 2018
RegMed Investors’ (RMi) motto: Q2/18 ends with Q3 coming attractions or reaction?
July 2, 2018
Mesoblast (MESO) $50 M debt deal, with a stock purchase, a re-payment plan from net sales
June 18, 2018
Solid Biosciences (SLDB) clinical hold removed on SGT-001 DMD (Duchenne muscular dystrophy) treatment
June 2, 2018
Regenerative Medicine Earnings Scorecard - Q1/18 - to date
May 31, 2018
Vericel (VCEL) proposes 5 M share $65 M offering at $13.00
May 16, 2018
Verastem Oncology (VSTM) proposes $35 M offering priced at $4.50 - SELL
May 9, 2018
AxoGen (AXGN) now proposes a 3 M share offering priced at $41.00 - SELL
April 26, 2018
Sangamo Therapeutics (SGMO) prices $200 M offering at $16.25 - SELL
April 9, 2018
Novartis (NVS) to acquire gene therapy company AveXis (AVXS) for $218 per share in a $8.7 billion deal
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
April 3, 2018
Cellectis (CLLS) and Allogene Therapeutics accelerate allogeneic off-the-shelf CAR T Therapies
April 2, 2018
RegMed Investors’ (RMi) motto: Worried about in 2018 (?), think eight (8) factors…
March 28, 2018
bluebird bio (BLUE)and Celgene (CELG) ink agreement to co-develop/promote Anti-BCMA CAR T cell therapy (bb2121) in the US
June 2, 2016
Kite Pharma (KITE) lights the fire, warming shareholders +$1.98 to $52.85
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.